Amendment #20 to the Amended and Restated Exclusive License Agreement dated October 21, 1998 between Endocyte, Inc. and Purdue Research Foundation, as amended
Exhibit 10.13
CONFIDENTIAL TREATMENT REQUESTED
Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for confidential treatment.
AMENDMENT #20
TO LICENSE AGREEMENT ID LA0003Endocyte
Between Purdue Research Foundation and Endocyte, Inc.
THIS AMENDMENT, made and entered into this 25th day of August, 2017 (“Amendment Effective Date”) amends the Amended and Restated License Agreement executed on October 21st, 1998, and all subsequent Amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte, Inc. (hereinafter known as LICENSEE).
NOW THEREFORE, the parties hereto do hereby agree as follows:
| 1. The following Eligible Disclosure is added to Appendix A of the AGREEMENT: |
| Title of Eligible Disclosure: | [*] |
| PRF Ref. No. | 67710 |
| Contributors of the Eligible Disclosure: | Phil Low-Purdue University Andrea Kasinski-Purdue University Loganathan Rangasamy-Purdue University |
| 2. The following Patents are added to Appendix A of the Agreement: |
| PRF Ref # | Title of Application | Application Number | Inventors | Filing Date | Country | Status |
| 67710-01 | [*] | [*] | Phil Low-Purdue University Andrea Kasinski-Purdue University Loganathan Rangasamy-Purdue University | 11/16/16 | US | Filed |
| 3. The rights granted to the above Eligible Disclosure and Patents are limited to use where the primary target of the Ligand is directed to a vitamin receptor. |
| 4. All other terms and conditions of the AGREEMENT remain unchanged and in effect. |
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Amendment Effective Date.
Purdue Research FoundationEndocyte, Inc.
By: _/s/ Brooke Beier____________By: _/s/ Mike Sherman___________________
Name: Brooke BeierName: Mike Sherman
Title: Executive Director, OTCTitle: President & CEO
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
